161 related articles for article (PubMed ID: 36627160)
1. Experience of the United Arab Emirates in the use of monoclonal antibody drug sotrovimab in high-risk vaccinated and unvaccinated patients with COVID-19: an observational cohort study.
Abdalateef S; Al Meheiri NM; Nassef M; Shorrab AA; Hashimi OAR; Allam S; Alnaqbi MS; Al-Rifai RH
BMJ Open; 2023 Jan; 13(1):e066095. PubMed ID: 36627160
[TBL] [Abstract][Full Text] [Related]
2. Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
Gupta A; Gonzalez-Rojas Y; Juarez E; Crespo Casal M; Moya J; Rodrigues Falci D; Sarkis E; Solis J; Zheng H; Scott N; Cathcart AL; Parra S; Sager JE; Austin D; Peppercorn A; Alexander E; Yeh WW; Brinson C; Aldinger M; Shapiro AE;
JAMA; 2022 Apr; 327(13):1236-1246. PubMed ID: 35285853
[TBL] [Abstract][Full Text] [Related]
3. Sotrovimab Lowers the Risk of COVID-19 Related Hospitalization or Death in a Large Population Cohort in the United Arab Emirates.
Saheb Sharif-Askari F; Ali Hussain Alsayed H; Tleyjeh I; Saheb Sharif-Askari N; Al Sayed Hussain A; Saddik B; Hamid Q; Halwani R
Clin Pharmacol Ther; 2022 Dec; 112(6):1214-1223. PubMed ID: 35780295
[TBL] [Abstract][Full Text] [Related]
4. Real-world effectiveness of sotrovimab and remdesivir for early treatment of high-risk hospitalized COVID-19 patients: A propensity score adjusted retrospective cohort study.
Koh LP; Chua SL; Vasoo S; Toh MPHS; Cutter JN; Nah PH; Leo YS; Tay JX; Young BE; Lye DC; Ong SWX
J Med Virol; 2023 Feb; 95(2):e28460. PubMed ID: 36602046
[TBL] [Abstract][Full Text] [Related]
5. Comparative effectiveness of sotrovimab and molnupiravir for prevention of severe covid-19 outcomes in patients in the community: observational cohort study with the OpenSAFELY platform.
Zheng B; Green ACA; Tazare J; Curtis HJ; Fisher L; Nab L; Schultze A; Mahalingasivam V; Parker EPK; Hulme WJ; Bacon SCJ; DeVito NJ; Bates C; Evans D; Inglesby P; Drysdale H; Davy S; Cockburn J; Morton CE; Hickman G; Ward T; Smith RM; Parry J; Hester F; Harper S; Mehrkar A; Eggo RM; Walker AJ; Evans SJW; Douglas IJ; MacKenna B; Goldacre B; Tomlinson LA
BMJ; 2022 Nov; 379():e071932. PubMed ID: 36384890
[TBL] [Abstract][Full Text] [Related]
6. Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19: Evidence from the US National COVID Cohort Collaborative (N3C).
Bell CF; Bobbili P; Desai R; Gibbons DC; Drysdale M; DerSarkissian M; Patel V; Birch HJ; Lloyd EJ; Zhang A; Duh MS;
Clin Drug Investig; 2024 Mar; 44(3):183-198. PubMed ID: 38379107
[TBL] [Abstract][Full Text] [Related]
7. Impact of the Sinopharm's BBIBP-CorV vaccine in preventing hospital admissions and death in infected vaccinees: Results from a retrospective study in the emirate of Abu Dhabi, United Arab Emirates (UAE).
Ismail AlHosani F; Eduardo Stanciole A; Aden B; Timoshkin A; Najim O; Abbas Zaher W; AlSayedsaleh AlDhaheri F; Al Mazrouie S; Rizvi TA; Mustafa F
Vaccine; 2022 Mar; 40(13):2003-2010. PubMed ID: 35193793
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal Antibodies for Treatment of SARS-CoV-2 Infection During Pregnancy : A Cohort Study.
McCreary EK; Lemon L; Megli C; Oakes A; Seymour CW;
Ann Intern Med; 2022 Dec; 175(12):1707-1715. PubMed ID: 36375150
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of sotrovimab for vaccinated or unvaccinated patients with mild-to-moderate COVID-19 in the omicron era.
Izumo T; Awano N; Kuse N; Sakamoto K; Takada K; Muto Y; Fujimoto K; Saiki A; Ito Y; Ota H; Inomata M
Drug Discov Ther; 2022 Jul; 16(3):124-127. PubMed ID: 35753770
[TBL] [Abstract][Full Text] [Related]
10. Real-World Evidence of the Neutralizing Monoclonal Antibody Sotrovimab for Preventing Hospitalization and Mortality in COVID-19 Outpatients.
Aggarwal NR; Beaty LE; Bennett TD; Carlson NE; Davis CB; Kwan BM; Mayer DA; Ong TC; Russell S; Steele J; Wogu AF; Wynia MK; Zane RD; Ginde AA
J Infect Dis; 2022 Dec; 226(12):2129-2136. PubMed ID: 35576581
[TBL] [Abstract][Full Text] [Related]
11. What Is the Efficacy of Sotrovimab in Reducing Disease Progression and Death in People with COVID-19 during the Omicron Era? Answers from a Real-Life Study.
De Vito A; Colpani A; Poliseno M; Diella L; Ieva FRP; Belati A; Papale R; Babudieri S; De Santis L; Saracino A; Lo Caputo S; Madeddu G
Viruses; 2023 Aug; 15(8):. PubMed ID: 37632099
[TBL] [Abstract][Full Text] [Related]
12. Use of Sotrovimab in a cohort of pregnant women with a high risk of COVID 19 progression: a single-center experience.
Frallonardo L; Vimercati A; Novara R; Lepera C; Ferrante I; Chiarello G; Cicinelli R; Mongelli M; Brindicci G; Segala FV; Santoro CR; Bavaro DF; Laforgia N; Cicinelli E; Saracino A; Di Gennaro F
Pathog Glob Health; 2023 Jul; 117(5):513-519. PubMed ID: 36896940
[TBL] [Abstract][Full Text] [Related]
13. Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab.
Gupta A; Gonzalez-Rojas Y; Juarez E; Crespo Casal M; Moya J; Falci DR; Sarkis E; Solis J; Zheng H; Scott N; Cathcart AL; Hebner CM; Sager J; Mogalian E; Tipple C; Peppercorn A; Alexander E; Pang PS; Free A; Brinson C; Aldinger M; Shapiro AE;
N Engl J Med; 2021 Nov; 385(21):1941-1950. PubMed ID: 34706189
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of pregnant women exposed to Sotrovimab for the treatment of COVID-19 in the BA.1 Omicron predominant era (PRESTO).
Tuan JJ; Sharma M; Kayani J; Davis MW; McManus D; Topal JE; Ogbuagu O
BMC Infect Dis; 2023 Apr; 23(1):258. PubMed ID: 37101135
[TBL] [Abstract][Full Text] [Related]
15. Real world effectiveness of sotrovimab in preventing COVID-19-related hospitalisation or death in patients infected with Omicron BA.2.
Behzad A; Mohamed A; Ali A; Niinuma S; Butler AE; Alqahtani M
J Infect Public Health; 2024 Feb; 17(2):315-320. PubMed ID: 38160562
[TBL] [Abstract][Full Text] [Related]
16. Use of sotrovimab in vaccinated versus unvaccinated COVID-19 patients in a resource-limited emergency department during the omicron surge.
Nene RV; Santodomingo MA; Balog B; Martinez H; Murillo E; Tomaszewski CA; LaFree A
J Am Coll Emerg Physicians Open; 2023 Jun; 4(3):e12958. PubMed ID: 37188260
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of bebtelovimab and sotrovimab treatment of solid organ transplant recipients with mild-to-moderate coronavirus disease 2019 during the Omicron epoch.
Yetmar ZA; Beam E; O'Horo JC; Seville MT; Brumble L; Ganesh R; Razonable RR
Transpl Infect Dis; 2022 Aug; 24(4):e13901. PubMed ID: 35848574
[TBL] [Abstract][Full Text] [Related]
18. Risk factors and early preventive measures for long COVID in non-hospitalized patients: analysis of a large cohort in the United Arab Emirates.
Saheb Sharif-Askari F; Ali Hussain Alsayed H; Saheb Sharif-Askari N; Saddik B; Al Sayed Hussain A; Halwani R
Public Health; 2024 May; 230():198-206. PubMed ID: 38574425
[TBL] [Abstract][Full Text] [Related]
19. Clinical efficacy of different monoclonal antibody regimens among non-hospitalised patients with mild to moderate COVID-19 at high risk for disease progression: a prospective cohort study.
Savoldi A; Morra M; De Nardo P; Cattelan AM; Mirandola M; Manfrin V; Scotton P; Giordani MT; Brollo L; Panese S; Lanzafame M; Scroccaro G; Berkell M; Lippi G; Konnova A; Smet M; Malhotra-Kumar S; Kumar-Singh S; Tacconelli E;
Eur J Clin Microbiol Infect Dis; 2022 Jul; 41(7):1065-1076. PubMed ID: 35727429
[TBL] [Abstract][Full Text] [Related]
20. Time to negative PCR conversion amongst high-risk patients with mild-to-moderate Omicron BA.1 and BA.2 COVID-19 treated with sotrovimab or nirmatrelvir.
Martin-Blondel G; Marcelin AG; Soulié C; Kaisaridi S; Lusivika-Nzinga C; Zafilaza K; Dorival C; Nailler L; Boston A; Ronchetti AM; Melenotte C; Cabié A; Choquet C; Trinh-Duc A; Lacombe K; Gaube G; Coustillères F; Pourcher V; Martellosio JP; Peiffer-Smadja N; Chauveau M; Housset P; Piroth L; Devaux M; Pialoux G; Martin A; Dubee V; Frey J; Le Bot A; Cazanave C; Petua P; Liblau R; Carrat F; Yordanov Y
Clin Microbiol Infect; 2023 Apr; 29(4):543.e5-543.e9. PubMed ID: 36586513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
